©2024 Stanford Medicine
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Not Recruiting
Trial ID: NCT01593397
Purpose
The primary objective of this study is to determine the influence of insulin resistance on
drug metabolism and response in obese subjects. The investigators hypothesize that expression
of adiponectin (a hormone secreted by fat tissue), and specific variants in the adiponectin
gene can predict the insulin resistance and drug response among obese subjects.
Official Title
Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity
Eligibility
Inclusion Criteria:
- Inclusion criteria include patients of adult age
- American Society of Anesthesiologists Class I, II, or III, and undergoing elective
surgical procedures requiring general anesthesia
- Body mass index greater than 35
Exclusion Criteria:
- Patients with evidence of hepatic, renal, or cardiovascular dysfunction
- History of difficult tracheal intubation, or adverse reaction to anesthesia shall be
excluded from the study
- Patients taking prescribed or over-the-counter anxiolytics, narcotics, or sleeping
aids, will also be excluded
Intervention(s):
drug: Propofol and Fentanyl administration
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jerry Ingrande, M.D., M.S.
650-723-7377